Investors and Media

Investor Relations

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Cancer is one of the most difficult diseases to treat. It is constantly changing, requiring new and more sophisticated therapies.

Replimune is pioneering a new generation of cancer treatments called oncolytic immunotherapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, generating a powerful patient-specific, systemic immune response.

Oncolytic immunotherapy enhances the effectiveness of immune checkpoint blockade and is expected to become the second cornerstone of immuno-oncology (IO) approaches, moving beyond incremental improvements in cancer treatment to help more patients overcome their disease.

Press Releases
Dec 28, 2023
WOBURN, Mass. , Dec. 28, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Philip Astley-Sparke , Chief Executive Officer of Replimune , will present at
Dec 05, 2023
RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to cemiplimab in the CERPASS clinical trial, but did not meet either of the two primary endpoints Positive data update for full 140 patients in the IGNYTE